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Abstract
Liver plays a key role in the metabolism of plasma apolipoproteins, endogenous lipids and
lipoproteins. Hepatocellular carcinoma (HCC) is one of the most common fatal malignant tumors
in China and in other Southeast Asian countries. This has been attributed to the high incidence of
hepatitis B infection. Hepatitis B proteins, such as the hepatitis B X protein (HBx) that is large
hepatitis B surface protein could regulate transcription of many candidate genes for liver
carcinogenesis. It has known that patients who suffered from acute hepatitis B could have lipid
disorders such as decreased plasma level of high-density lipoproteins (HDL). Furthermore,
aberrations of lipid metabolism are often seen in the chronic hepatitis B infection.
Plasma lipid profiles could be changed under HCC. In majority of the reports in HCC, plasma levels
of triglycerides (TG), cholesterol, free fatty acids (FFA), HDL, low-density lipoproteins (LDL),
lipoprotein (a) (Lp(a)), apolipoprotein AI (apoAI) and apoB were slight to significantly decreased,
however, in some cases plasma levels of TG and Lp(a) might be increased. It has been suggested
that analysis of plasma levels of lipids, lipoproteins and apolipoproteins in the patients suffered from
HCC reflects on the hepatic cellular impairment status. Studies revealed that alterations seen in
the plasma levels of lipids, lipoproteins and apolipoproteins reflecting patients' pathologic
conditions. Decreased serum levels of cholesterol and apoAI may indicate a poor prognosis.
Human leukaemic cells and certain tumor tissues have a higher receptor-mediated uptake of HDL
and LDL than the corresponding normal cells or tissues. LDL and HDL have therefore been
proposed as a carrier for the water-insoluble anti-cancer agents.
Introduction
Liver is one of the most important organs in energy
metabolism. Most plasma apolipoproteins, endogenous
lipids and lipoproteins are synthesized in the liver [1,2],
which depends on the integrity of cellular functions of
liver [2,3]. Under normal physiological conditions, liver
ensures homeostasis of lipid and lipoprotein metabolism
[4]. Hepatic cellular damage and HCC impairs these proc-
esses, leading to alterations in plasma lipid and lipopro-
tein patterns. Mortality due to liver cancer is the fifth
common malignant tumor worldwide [5], and it is closely
related to the infections of hepatitis B virus (HBV) [6-8]
and hepatitis C virus (HCV) [9]. HBV proteins, such as the
hepatitis B X protein (HBx) that is large hepatitis B surface
protein could regulate transcription of many candidate
genes for liver carcinogenesis [10,11]. As HBV and HCV
infections are quite common in China and in other South-
east Asian countries [12-14], the mortality of HCC is 20,4/
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100,000 in the population of China, corresponding to
about 18.8% of all fatal malignant tumors [12]. Hepatic
diseases differ from most other causes of secondary dysli-
pidemia in that the circulating lipoproteins are not only
present in abnormal amounts but they frequently also
have abnormal composition, electrophoretic mobility
and appearance [15]. It has been demonstrated that
patients suffered from acute hepatitis B could have lipid
disorders, for instance, decreased plasma HDL [16,17].
The aberrations of lipid metabolism are often seen in the
chronic hepatitis B infection too [18]. HDL and its major
apolipoproteins, apoAI and apoAII, are frequently
reduced in the patients suffered from cirrhosis or HCC
[15]. Decrease in the level of serum LDL cholesterol in
patients with liver disease was significantly correlated to
the increasing severity of the disease [19-22]. In the
present review we discussed aberrations of lipid profiles in
the patients suffered from HCC. Decreased serum levels of
cholesterol and apoAI may indicate a poor prognosis [22-
24]. The changes of lipid profiles under HCC are listed in
table 1.
Influence of HCC on metabolism of triglycerides, 
cholesterol and free fatty acids
The patients with HCC frequently have other liver dis-
eases such as chronic hepatitis and cirrhosis. All these con-
ditions (hepatitis and cirrhosis of the liver) are often
associated with plasma lipid and lipoprotein aberrations
[25]. It has been demonstrated that plasma triglycerides
(TG) decreased by 20–30% in the patients with HCC [21].
In contrast, Alsabti [26] reported that serum TG in HCC
patients were increased when compared to those with cir-
rhosis. Ooi, et al., [22] reported that plasma TG levels in
HCC patients were not significantly different compared
with controls. These results emphasize the fact that
changes of plasma lipid profile may not always imply the
presence of HCC and one need to exercise caution in
interpreting these results.
It is known that lipids and lipoprotein metabolism could
be regulated by cytokines. For instance, interleukin-6 (IL-
6), tumor necrosis factor (TNF-α), IL-1 may inhibit TG
synthesis [27]. Tumor cells are known to produce large
amounts of pro-inflammatory cytokines that, in turn, may
suppress plasma TG levels. Argiles, et al., reported that IL-
1 profoundly affects lipid metabolism by delaying intesti-
nal absorption and decreasing tissue uptake [28]. IL-2
could induce severe hypocholesterolemia that is mediated
by the inhibition of lecithin:cholesteryl acyltransferase
(LCAT) activity [29]. IL-1 and IL-6 significantly decreased
microsomal triglyceride transfer protein (MTP) mRNA
levels in HepG2 cells [30]. It is believed that MTP is
related to the synthesis of very low density lipoprotein
(VLDL) [31]. In addition, these cytokines could also
decrease lipolysis in vivo [32]. Similar results have been
reported in other types of cancers [33].
About 80% endogenous cholesterol are synthesized in the
hepatocellular microsomes that contain cholesterol syn-
thesis enzymes [34,35]. In HCC and chronic liver diseases
the synthesis and metabolism of cholesterol are impaired.
It leads to a decrease in plasma cholesterol levels
[19,21,22,36]. Li reported [37], in a forward investigation,
the relationship between serum cholesterol and occur-
rence of cancers in 9021 employees aged from 35 to 64
years old. No evidence of association of serum cholesterol
level with total cancer mortality was seen by Log-rank
trend test. But there was a significant negative correlation
between serum cholesterol level and HCC (P < 0.05). This
negative correlation also existed between serum choles-
terol level and chronic hepatitis and liver cirrhosis. Simi-
lar results were described in patients with gastrointestinal
Table 1: Summarization of serum lipid/lipoprotein changes under HCC
Lipids/Lipoproteins Changes under liver cancer References
Triglycerides ↑
↓↓ or-
[26]
[21], [22]
Total cholesterol ↑
↓ to ↓↓
[26]
[19], [21], [22], [36]
Free fatty acids ↑ [52]
Lp(a) ↑
↓ to ↓↓
[75]
[21], [72], [73]
HDL ↓↓ [19], [21], [22], [36], [79]
LDL ↓ [19]
ApoAI ↑ (proapoAI)
↓↓
[81]
[19], [24], [23], [82]
ApoAII ↓↓ [24], [23]
ApoB ↓ [83]
ApoM ↓↓ Hepatic expression Unpublished data
↑ slight increase; ↑ slight decrease; ↓↓ significant decrease; – no change.Lipids in Health and Disease 2006, 5:4 http://www.lipidworld.com/content/5/1/4
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cancer, however, lower cholesterol levels are not related to
the cancer stages [38]. Decreased serum cholesterol con-
centrations were also found in other cancers [39-41],
which are probably related to the increased consumption
of cholesterol by the tumor cells, as cholesterol levels in
the hepatoma tissues were doubled compared to the con-
trol tissues [42]. In addition, it has been reported that syn-
thesis of cholesterol is reduced under cancers [43], and
moderate increases of serum cholesterol levels and
increased body mass index (BMI) may have a protective
effect on cancer mortality [44,45]. It was observed that the
plasma HDL-cholesterol was inversely correlated to the
cholesterol levels in the tumor tissues in cancer patients
[46]. Because the use and storage of cholesterol are
increased within the tumor tissues during growth, it is
possible to hypothesize that lower HDL levels observed in
patients with gastrointestinal cancer are associated with
the increased cholesterol metabolism in these proliferat-
ing tissues [46].
Liver is a key organ for the metabolism of free fatty acids
(FFA) [47], and FFA are the source of TG synthesis in the
liver [48]. The extracellular FFA pool in tumors undergoes
continuous turnover, utilizing adipose tissue storage as a
source [49]. It is reported that plasma FFA are increased in
tumor bearing animals [50]. Increased plasma FFA is
attributed to the hypermetabolic state in cancers [51]. Li,
et al., [52] reported that proportions of plasma saturated
and monounsaturated fatty acids in the HCC patients
were significantly increased compared to the controls.
Similar results were found in the patients with breast can-
cer suggesting that this could be a common finding in
tumors [53]. It is believed that these FFA could be used as
metabolic substrates by the tumor cells [54]. Hanai, et al.
[55] evaluated seventeen hepatectomized cases (12 cases
of HCC and 5 cases of metastatic liver cancer). In HCC tis-
sues, the levels of alpha-linolenic acid (LA) and docosa-
hexaenoic acid (DHA) were significantly less than those in
the reference tissues those normal tissues surrounding
tumors. Wood, et al., [56] analyzed total lipid extracts of
liver tissue from 14 HCC patients and demonstrated that
ratio of saturate C18 to unsaturated C18 in the tumor tis-
sues were significantly and consistently lower than those
corresponding non-tumor tissues. Palmitic acid was the
most representative saturated FFA, while unsaturated FFA
was represent, in decreasing order, by oleic, linoleic and
arachidonic acids (AA) [57]. Available evidence [58] is
consistent with the possibility that selective changes in the
hepatocellular metabolism of long-chain fatty acids may
contribute significantly to the activity of the extramito-
chondrial pathways, which may also contribute to liver
injury and tumorigenesis. De Alaniz and Marra [59] dem-
onstrated a significant contribution of the stearoyl-CoA
desaturase system to the high levels of oleic acid (OA)
present in hepatoma cells. Peroxisome proliferators are
diverse group of chemicals which are regarded as rodent
hepatocarcinogens and/or liver tumor promoters [60]. It
has been demonstrated that peroxisome proliferators
could increase hepatocyte proliferation and cause liver
tumors in rodents, which is related to transcriptional acti-
vation of peroxisome proliferators-activated receptor
(PPAR)-α regulated genes and the resulting excessive gen-
eration of H2O2. Evidence from mice lacking fatty acyl-
CoA oxidase (AOX), PPAR-α and PPAR-α/AOX has con-
firmed the role of PPAR-α in the development of HCC
[61-63]. As PPAR-γ functions as a regulator of cell survival
and growth in the HCC, PPAR-γ therefore represents a
putative molecular target for chemopreventive therapy or
inhibition of HCC growth [64]. In addition, decreased
expression of hepatic PPAR-α functions as one mecha-
nism underlying the pathogenesis of HCV infection,
PPAR-α may serve as a new therapeutic target in tradi-
tional treatment of HCV-induced liver injury [65].
Plasma lipoprotein pattern in the patients with HCC
Liver represents the main site of lipoprotein (a) (Lp(a))
synthesis [66-68]. Half-life of Lp(a) is about 3.3–3.9 days
in human plasma [69], which is influenced in the early
stage when liver function was impaired [66]. Lp(a) is syn-
thesized and metabolized independently of other plasma
lipoproteins, and Lp(a) level is not influenced by various
dietary manipulations [70]. Motta, et al., [21] demon-
strated that Lp(a) levels were significantly lower in the
HCC patients (5.7 ± 2.08 mg/dl) than in the controls
(16.78 ± 16.24 mg/dl). Higuchi, et al., [71] elucidated that
influences of serum Lp(a) levels in some tumors could be
characterized by the production and deliverance of
cytokines. It has been reported that serum Lp(a) were sig-
nificantly lower in the HCC patients [72,73]. However,
Geiss, et al., [74] observed patients with acute hepatitis
showed a marked increase in Lp(a) concentration, i.e., 7
mg/dL in acute stage and 32 mg/dL in the convalescence
of the disease. Basili, et al., reported that Lp(a) could also
be increased in the patients suffered from HCC together
with cirrhosis [75]. It has been demonstrated that Lp(a)
together with ferritin and alpha-fetoprotein could be a
sensitive and early marker to evaluate liver function [21].
As Lp(a) has positive correlation with the hepatic status, it
has been suggested that Lp(a) could be considered as a
index of liver function [21,68,76].
The origin and fate of HDL are less well understood than
other lipoproteins. HDL may be formed both in the intes-
tine and in the liver. During lipolysis of TG-rich lipopro-
teins, HDL particles are also formed. ApoAI and apoAII
are the major apolipoproteins of the HDL. Production
rate of apoA-I is an important determinant of the variabil-
ity of plasma HDL concentrations. It is influenced by
many factors and apoA-I transcriptional regulation has an
impact on plasma HDL concentrations. Nutritional inter-Lipids in Health and Disease 2006, 5:4 http://www.lipidworld.com/content/5/1/4
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ventions such as, a switch from high-carbohydrate to a
high-fat diet appears to exert their major effect on the pro-
duction rate of apoA-I rather than on clearance [20,77].
HDL plays a key role in the reverse cholesterol transport
pathway (RCTP) [24,78]. It has been demonstrated that
HDL fraction offers a new approach to study liver diseases
[19]. Ahaneku, et al., [36] analyzed HDL-fraction levels
including HDL-cholesterol (HDL-C), HDL-phospholipids
(HDL-PL) and the ratio of HDL-C/HDL-PL, in HCC
patients and compared with the controls. They found that
plasma HDL-C, HDL-PL and HDL-C/HDL-PL were signif-
icantly lower in HCC patients than those in the controls.
Motta, et al., [21] studied 40 patients with HCC, and eval-
uated the LDL-C, HDL-C. In patients with HCC, LDL-C
level was significantly lower than in the controls, but
HDL-C did not show a statistically significant difference
to the controls. Kanel, et al., [79] reported that patients
with primary or metastatic liver cancer had strikingly
decreased HDL-C. Ooi, et al., [22] suggested that HDL-C
may be clinically useful to reflect the pathologic condi-
tions, and can be used to evaluate the severity of liver dis-
eases. In the metastatic liver cancer showed a lower HDL-
fraction level too, even lower than those in the HCC
patients. Also, Fujii, et al., [23] found existence of HDL
with an abnormal apoprotein composition or a more pro-
found decrease of HDL3 than those of HDL2 in severe
hepatocellular dysfunction of cholestasis. Cooper, et al.,
[19] observed that there was a rapid decreases of HDL-
cholesterol and LDL-cholesterol immediately after hepatic
resection. Lipid profiles are different in the cirrhosis
patients with or without HCC. In cirrhosis with HCC
plasma phospholipid levels showed a significant negative
correlation with total bilirubin and alanine aminotrans-
ferase. Total cholesterol (TC), phospholipids (PL) and the
ratio of TC/PL were elevated, while HDL-C, HDL-PL,
HDL-C/TC and HDL-PL/PL were normal. It is suggested
that variations in the level of plasma lipids and lipopro-
teins may assist in describing the nature of these two
forms of liver disease [36].
Influence of HCC on apolipoproteins
Liver is the main organ for the synthesis, storage, transpor-
tation and degradation of some apolipoproteins [20].
Each protein may be influenced by liver disease in a differ-
ent way, and serum lipoprotein concentrations with faster
turn-over are more reduced with respect to those with
slower turn-over [80]. Serum concentrations of apoAI and
A-II were significantly lower in the patients suffered from
HCC [23,24], but an increase in the proportion of
proapoAI was found in patients with HCC [81]. The pro-
portion of proapoAI showed a tendency toward increase
under advanced liver damage because liver participates in
the process of converting proapoAI to the mature apoAI.
It is suggested that plasma apoAI could reflect the hepato-
cellular dysfunction [2,19,82]. The pattern of changes in
the serum apoAI levels may be a good indicator of the
hepatic protein synthetic ability during the perioperative
period after hepatectomy [82]. ApoB in the liver was an
important glycoprotein for transportation of VLDL and
LDL, in liver cells hyperexpression of HBx caused accom-
modation of MTG, HBx could increase the expression of
beta-d-mannoside-,-N-acetylglucosaminyl transferase-III
(GnT-III), and it could inhibit apoB secretion and
enhanced the accumulation of intracellular triglyceride
and cholesterol [83]. Ooi et al., [22] reported that slow
alpha HDL appeared in the metastatic liver cancer in the
early-middle stages, during slight bile stagnation, and
accompanied by increases of apo E levels [84]. In our pre-
liminary study we have observed that apolipoprotein M
(apoM) mRNA levels were significantly lower in the HCC
tissues than those in the normal hepatic tissues surround-
ing tumors (non-published data). Up to date there is no
data reported concerning other apolipoproteins in rela-
tion to liver cancer.
Using HDL and LDL as carriers for the water-insoluble 
anti-cancer drugs
HDL transports cholesterol to liver cells, where they are
recognized and taken up via specific receptors. Cholesteryl
esters within HDL are selectively uptaken by hepatocytes
via the scavenger receptor class B type I (SR-BI). An inter-
esting feature of SR-BI is that the receptor selectively trans-
locates HDL-cholesteryl esters from the lipoprotein
particle to the cytosol of the liver parenchymal cells with-
out a parallel uptake of the apolipoproteins and this prop-
erty may allow for the delivery of its loaded drugs
avoiding lysosomal degradation [85]. As HDL and LDL
have high affinity and could be accumulated in tumor
cells [86-88], they have been used as carriers for delivery
of anti-tumor drugs into hepatoma cells to treat HCC
[85,89-93]. Masquelier, et al., [94] investigated the possi-
bilities to use LDL as a drug carrier to increase the selectiv-
ity of anti-tumor drugs in cancer chemotherapy. It has
been demonstrated that both HDL and LDL may be used
as endogenous targeting carriers into tumor cells, which
have high lipoprotein-receptor activities, in animal mod-
els [88,95]. Anti-cancer drug-HDL complexes work as effi-
cient drug delivery vehicles due to the ability of cancer
cells to acquire HDL core components [89,96]. Complex
of anti-cancer drugs with HDL and LDL does not influ-
ence characteristics of the drugs [92]. Lacko, et al., demon-
strated that administration of anti-cancer drug-HDL
complex may reduce toxic side-effects during the chemo-
therapy [89]. Lou, et al., reported in a cell culture system
that cellular uptake of recombinant HDL-aclacinomycin
(ACM) by the SMMC-7721 hepatoma cells was signifi-
cantly higher than that of free ACM at the concentration
range of 0.5–10 µg/mL (P < 0.01). Cytotoxicity of recom-
binant HDL-ACM to SMMC-7721 cells was significantly
higher than that of free ACM at concentration range of lessLipids in Health and Disease 2006, 5:4 http://www.lipidworld.com/content/5/1/4
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than 5 µg/mL (P < 0.01) and IC50 of recombinant HDL-
ACM was lower than IC50 of free ACM (1.68 nmol/L vs 3
nmol/L) [85]. Chu, et al., coupled doxorubicin (DOX) to
human LDL to form a LDL-DOX complex. When the com-
plexes injected into mice, LDL-DOX was more accumu-
lated in liver than free DOX. In contrast, LDL-DOX was
less accumulated in heart than free DOX [97]. It suggested
that both HDL and LDL could be used as carriers to con-
jugate water-insoluble anti-cancer drugs leads to a higher
accumulation of the drugs locally and specifically.
Conclusion
It is thus evident that liver plays a vital role in the produc-
tion and catabolism of plasma lipoproteins and apolipo-
proteins. Plasma lipid profiles could be changed in HCC.
It has been summarized in the Table 1. Analysis of serum
levels of lipids, lipoproteins and apolipoproteins in the
patients suffered from HCC may reflect the condition of
hepatic cellular impairment, and may also be used as an
indicator to evaluate patient's prognosis. It is suggested
that variations in the levels of plasma lipids and lipopro-
teins may assist in describing the nature of HCC with or
without cirrhosis. The serum apoAI and Lp(a) levels may
considered as the index of liver impairments under
chronic or HCC. In addition, HDL and LDL had been used
as a carrier for delivering chemotherapeutic drugs in HCC
and other cancers.
Abbreviations
HDL, high density lipoprotein; VLDL, very low density
lipoprotein; LDL, low density lipoprotein; HCC, hepato-
cellular carcinoma; Lp (a), lipoprotein (a), HBx, X protein
of hepatitis B virus; GnT-III, beta-d-mannoside-,-N-
acetylglucosaminyl transferase-III; apoB, Apolipoprotein
B; Lp-X, lipoprotein X; FFA, free fatty acids; OA, oleic acid
; AA, arachidonic acid; DHA, docosahexaenoic acid; SR-BI,
scavenger receptor class B type I.
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